Therapeutic Areas
Oncology
Stage
Commercial
Modalities
Small molecule

Nanoform General Information

Commercial stage nanotechnology company providing API particle size reduction services. Successfully completed clinical studies demonstrating bioavailability improvements for nanoformed drugs.

Contact Information

Website
Primary Industry
CDMO
Corporate Office
Helsinki,
Finland

Drug Pipeline

enzalutamide
Clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Nanoform's pipeline data

Book a demo

Key Partnerships

AstraZeneca, Boehringer Ingelheim, Takeda, Celanese, Herantis, TargTex, PlusVitech, CBC, Pharmanovia

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Nanoform Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Nanoform's complete valuation and funding history, request access »